Pancreatic cancer: from state-of-the-art treatments to promising novel therapies (Q38396634)

2 September 2017

1 reference

title

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies (English)

1 reference

2 September 2017

1 reference

2

1 reference

PubMed ID

25824606

2 September 2017

Ignacio Garrido-Laguna

series ordinal

1

object named as

Ignacio Garrido-Laguna

1 reference

PubMed ID

25824606

2 September 2017

language of work or name

English

0 references

publication date

31 March 2015

1 reference

Nature Reviews Clinical Oncology

2 September 2017

1 reference

2 September 2017

12

1 reference

2 September 2017

6

1 reference

2 September 2017

319-334

1 reference

2 September 2017

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

EMT and dissemination precede pancreatic tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Most Pancreatic Cancer Resections are R1 Resections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Chemotherapy for pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Improvement of surgical results for pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Variation in hospital mortality associated with inpatient surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Genome sequencing identifies a basis for everolimus sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Clinical and molecular characterization of HER2 amplified-pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Mining the genomes of exceptional responders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Biomarkers: exceptional responders-discovering predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

US National Cancer Institute's new Ras project targets an old foe.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Mutant KRAS is a druggable target for pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Improved survival with MEK inhibition in BRAF-mutated melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Janus kinases: components of multiple signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

JAK V617F missense mutation is absent in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Evidence for the importance of personalized molecular profiling in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Otto Warburg's contributions to current concepts of cancer metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Conceptual framework for cutting the pancreatic cancer fuel supply

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Cancer-associated stromal fibroblasts promote pancreatic tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A paracrine requirement for hedgehog signalling in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Stromal response to Hedgehog signaling restrains pancreatic cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Identification of pancreatic cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

The immune network in pancreatic cancer development and progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.53

10.1038/NRCLINONC.2015.53

31 March 2020

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25824606